Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Lung Neoplasms 20Neoplasms 4Neoplasm Metastasis 3Carcinoma 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non Small Cell Lung Cancer Metastatic 1NSCLC 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1

Interventions

pembrolizumab 1osimertinib 1durvalumab 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × osimertinib × 90 days × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡